Table 2.
Characteristics of SBRT Studies (2001–2012) Included in Current Meta-analysis.
| First author | Year | Study. design |
Sampl e size |
Male (%) |
Median/ mean age |
IA/I (%) |
Path. (%) |
Dose range | BED10 | F/U (mo) |
|---|---|---|---|---|---|---|---|---|---|---|
| Nagata Y24 | 2005 | P | 45 | 74 | 77 (51–87) | 71 | 100.0 | 12Gy × 4 | 105.6 | 30 |
| Nyman J25 | 2006 | R | 45 | 57 | 74 (58–84) | 40 | 80.0 | 15Gy × 3 | 112.5 | 43 (24–74) |
| Timmerman R26 | 2006 | R | 70 | 74 | 70 (51–86) | 50 | / | 20Gy × 3 | 180 | 17.5 (0.6–44) |
| Zimmermann F27 | 2006 | R | 68 | 71 | 76 | 100 | 100.0 | 12.5Gy× 3; 7Gy× 5 (at 60%-isodose) | 84.4;59.5 | 17(3–44) |
| Koto M28 | 2007 | P | 31 | 81 | 77 (60–83) | 61 | 100.0 | 15Gy × 3; 7.5Gy × 8 | 112.5;105 | 32 (4–87) |
| Onishi H29 | 2007 | R | 257 | NA | 74 (39–92) | 64 | NA | 4.4~35/1-14F× | 117 (100–180) | 38 (2–128) |
| Fritz P30 | 2008 | R | 40 | 80 | 74 (59–82) | 55 | 100 | 30Gy×1 | 120Gy (isocenter) | 20 (6–61.5) |
| Lagerwaard FJ31 | 2008 | R | 206 | 57 | 73 | 59 | 31.0 | 20Gy × 3; 12Gy × 5; 7.5Gy × 8 | 132 | 12 |
| Onimaru R32 | 2008 | P | 41 | 69 | 76 (52–85) | 61.0 | NA | 10Gy × 4; 12Gy × 4 | 80;105.6 | 27 |
| Salazar OM33 | 2008 | R | 60 | NA | NA | 75 | NA | 13Gy × 4 | 119.6 | NA |
| Baumann P7 | 2009 | P | 57 | 44 | 75 (59–87) | 70.2 | NA | 15Gy × 3 | 112.5 | 35 (4–47) |
| Fakiris AJ34 | 2009 | P | 70 | NA | NA | 48.6 | NA | 20Gy × 3 (IA); 22Gy × 3 (IB) | 180; 211.2 | 50.2 |
| Kopek N35 | 2009 | R | 88 | 50 | 72 (47–88) | 58.6 | 100.0 | 15/22.5Gy × 3 | 112.5; 219.5 | 44 (1.6–96.5) |
| Stephans KL36 | 2009 | R | 56 | 52 | 72 (49–89) | 75.0 | NA | 10Gy × 5 | 100 | 19.8 |
| Takeda A37 | 2009 | R | 63 | 63 | 78 (56–91) | 60.3 | 82.5 | 10Gy × 5 | 100 | 31 (10–72) |
| Baba F38 | 2010 | R | 124 | 68 | 77 (29–89) | 70.2 | 91.9 | 11Gy × 4 (1.6%); 12Gy × 4; 13Gy × 4 | 92.4; 105.6; 119.6 | 26 (7–66) |
| Bradley JD39 | 2010 | P | 91 | 47 | 71 (31–93) | 72.5 | 86.3 | 18Gy × 3 | 151.2 | 18 (6–42) |
| Burdick MJ40 | 2010 | R | 72 | 52 | 74 (44–89) | 68.1 | 68.1 | 20Gy × 3; 10Gy × 5; 5Gy × 10 | 180; 100; 75 | 36 |
| Dunlap NE41 | 2010 | R | 40 | NA | 73 (54–87) | 67.5 | 100.0 | 42-60/3-5FX | 150 | 12.5 (2–35) |
| Hamamoto Y42 | 2010 | R | 52 | 70 | 78 (58–90) | 76.8 | 67.3 | 12Gy × 4 | 105.6 | 14 (3–34) |
| Ricardi U43 | 2010 | P | 62 | 84 | 73 (53–83) | 69.4 | 100.0 | 15Gy × 3 | 112.5 | 28 (9–60.7) |
| Timmerman R8 | 2010 | P | 59 | 38 | 72 (48–89) | 80.0 | 100.0 | 18Gy × 3 | 151.2 | 34.4 (4.8–49.9) |
| Van Der Voort Van Zyp NC44 | 2010 | P | 39 | NA | 77 (55–87) | 58.9 | NA | 20Gy × 3 | 180 | 17 |
| Bral S45 | 2011 | P | 40 | 83 | 73 (54–86) | 65 | 100 | 20Gy × 3; 15Gy × 4 | 180; 150 | 16 (5–33) |
| Lanni TB46 | 2011 | R | 45 | 40 | 76 (63–90) | 71 | 100 | 12Gy × 4; 12Gy × 5 | 105.6; 140 | 36 |
| Matsuo Y47 | 2011 | R | 101 | 73 | 77 (62–87) | 58.9 | 100.0 | 12Gy × 4 | 105.6 | 31.4 (4.2–118) |
| Nath SK48 | 2011 | R | 58 | 63 | 79 (60–88) | 58.9 | 100.0 | 10Gy × 5; 12Gy × 4; 13Gy × 4 | 100; 105.6; 119.6 | 17 (4–42) |
| Turzer M49 | 2011 | R | 36 | 28 | 74 (54–85) | 53 | 73.7 | 15Gy × 3 | 112.5 | 13.8 (0–21) |
| Widder50 | 2011 | P | 202 | 73 | 76 (46–93) | NA | 29 | 20Gy × 3; 12Gy × 5; 7.5Gy× 8 | 180; 140; 105 | 13 |
| Senthi S6 | 2012 | R | 676 | 61 | 73 (47–92) | 56 | 35 | 20Gy × 3 or 18Gy × 3; 12Gy × 5 or 11Gy × 5; 7.5Gy × 8 | 151·2; 115·5; 105 | 32.9(14.9–50.9) |
| Taremi M51 | 2012 | P | 108 | 49 | 73 (48–90) | 79.6 | 69.4 | 20Gy × 3; 18Gy × 3; 12Gy × 4; 7.5Gy× 8; 5Gy × 10 (9.6%) | 180; 151.2; 105. 6; 105; 75 | 19.1 (1–55.7) |
Note: BED10: biological equivalent dose with α/β=10; F/U (mo): follow-up period in months; Path (%): percentage of disease with pathological confirmation; P: prospective study; R: retrospective study; NA: not reported or not specified